List of Excipients in Branded Drug BENZPHETAMINE HYDROCHLORIDE

Generic Drugs Containing BENZPHETAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
KVK-TECH INC	benzphetamine hydrochloride	10702-040	CARNAUBA WAX
KVK-TECH INC	benzphetamine hydrochloride	10702-040	CELLULOSE, MICROCRYSTALLINE
KVK-TECH INC	benzphetamine hydrochloride	10702-040	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in BENZPHETAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
6	CALCIUM STEARATE
9	CARNAUBA WAX
10	CELLULOSE, MICROCRYSTALLINE

Benzphetamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Benzphetamine hydrochloride is an established oral anorectic with limited remaining formulation exclusivity and a narrow commercial market. The strongest opportunities are generic supply, excipient-led differentiation, controlled-substance compliance, and lifecycle reformulation rather than new chemical entity development. Immediate-release tablets containing 25 mg or 50 mg remain the most commercially defensible dosage form. A new formulation would likely require a 505(b)(2) application unless it qualifies as an ANDA referencing an approved product.

What is benzphetamine hydrochloride used for?

Benzphetamine hydrochloride is a sympathomimetic amine indicated for short-term use as an adjunct to caloric restriction in the management of exogenous obesity. FDA labeling limits treatment to patients with an initial body mass index of at least 30 kg/m², or at least 27 kg/m² when other risk factors are present, under the applicable historical labeling framework (FDA, 2023a).

The drug is supplied as immediate-release oral tablets in 25 mg and 50 mg strengths. Benzphetamine is a Schedule III controlled substance in the United States because of its pharmacologic relationship to amphetamine and its potential for abuse and dependence (FDA, 2023a; DEA, 2024).

Attribute	Benzphetamine hydrochloride
Therapeutic class	Sympathomimetic anorectic
Dosage form	Immediate-release tablet
Strengths	25 mg and 50 mg
Route	Oral
U.S. controlled-substance schedule	Schedule III
Historical reference brand	Didrex
Primary regulatory pathway for generics	ANDA
Potential pathway for reformulation	505(b)(2)
Treatment positioning	Short-term adjunct to diet and caloric restriction
Current competitive context	Generic and legacy product market

The commercial market is structurally constrained by the availability of newer chronic weight-management therapies, including GLP-1 receptor agonists and dual incretin products. Benzphetamine may still have value in price-sensitive, short-duration, or controlled-substance prescribing segments, but it does not compete directly with the clinical and commercial positioning of semaglutide, tirzepatide, or other chronic obesity treatments.

What excipients are used in benzphetamine hydrochloride tablets?

The excipient composition depends on the manufacturer and approved product. Public labeling for benzphetamine hydrochloride tablets identifies conventional tablet excipients, which may include lactose, starch, talc, and magnesium stearate or functionally equivalent materials (DailyMed, 2024).

Because generic manufacturers can use different inactive ingredients, the excipient strategy should be evaluated at the product level rather than inferred solely from the active pharmaceutical ingredient.

Core excipient functions

Formulation function	Common excipient category	Commercial purpose
Dilution and tablet mass	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Supports tablet size and content uniformity
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves mechanical strength
Disintegrant	Starch, croscarmellose sodium, sodium starch glycolate	Supports immediate release
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces tooling friction
Antiadherent	Talc	Limits sticking and picking
Colorant	Approved color additives	Supports product identification
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance and handling

For a low-dose, immediate-release controlled substance, content uniformity, tablet hardness, disintegration, dissolution, and stability are more important than complex drug-delivery technology. Excessive excipient loading can increase tablet size without creating a meaningful clinical benefit.

How should an excipient strategy be designed for benzphetamine hydrochloride?

The preferred strategy is a robust, conventional immediate-release formulation with a low manufacturing-risk excipient system.

1. Prioritize content uniformity

Benzphetamine hydrochloride is present at a relatively low dose compared with the total tablet mass. The formulation should control segregation during blending, compression, transfer, and packaging. A particle-size and density assessment of the active ingredient is essential because differences between active and excipient particles can produce dose variability.

A practical approach is geometric dilution combined with a high-functionality filler-binder, followed by validated blending controls. Direct compression may be attractive if the active and excipient physical properties are suitable. Wet granulation can improve uniformity and flow but adds process steps, residual-moisture risk, and scale-up complexity.

2. Maintain immediate-release performance

The product should avoid excipient systems that delay dissolution or create unnecessary release variability. A conventional disintegrant and water-soluble or moderately soluble filler system is generally more appropriate than a matrix former or multiparticulate design.

Dissolution should be compared with the reference-listed drug across relevant pH conditions. A reformulated product with materially different dissolution behavior could trigger additional regulatory scrutiny, particularly if the proposed product uses a 505(b)(2) pathway.

3. Manage hygroscopicity and salt stability

Benzphetamine hydrochloride is an ionic salt. Moisture exposure can affect powder flow, compaction, chemical stability, and dissolution. The formulation should be evaluated under accelerated and long-term stability conditions with attention to:

• Assay and degradation products
• Water content
• Tablet hardness and friability
• Disintegration and dissolution
• Color and physical appearance
• Packaging moisture transmission
• Extractables and leachables where protective packaging is used

Aluminum-aluminum blister packaging or high-barrier bottles may provide a commercial advantage if stability data show sensitivity to moisture or oxygen. Packaging selection also has a controlled-substance function because unit-dose packaging can improve inventory control and reduce dispensing errors.

4. Reduce excipient-related exclusions

A lactose-free version could address patients with lactose intolerance or prescriber preference. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected co-processed excipients could replace lactose, subject to compatibility and performance testing.

A gluten-free positioning may be possible if the full manufacturing supply chain is controlled and the product complies with applicable FDA gluten-labeling requirements. The commercial value is likely modest because the product is swallowed as a tablet and has no prominent dietary or pediatric positioning.

5. Consider coating as a product-identification tool

A film coat can differentiate 25 mg and 50 mg tablets, improve swallowability, and support tablet integrity. It should not be marketed as abuse-deterrent unless the product has been specifically developed, studied, and reviewed for that purpose. Conventional coating does not eliminate the abuse potential associated with the active ingredient.

What formulation patents protect benzphetamine hydrochloride?

Benzphetamine hydrochloride has a mature patent position centered on the active ingredient and legacy product development rather than modern excipient technology. The original brand product, Didrex, was approved decades ago, and any original compound or formulation patents would have expired long before the current generic market.

For a new manufacturer, the relevant IP review should focus on:

1. Live formulation patents covering specific excipient combinations or release profiles.
2. Method-of-use patents covering obesity treatment, dosing, or patient subgroups.
3. Manufacturing patents covering particle engineering, granulation, or tablet compression.
4. Trademark rights associated with legacy brands.
5. FDA Orange Book listings and reference-product labeling.

A conventional generic immediate-release tablet is unlikely to obtain meaningful patent protection solely from replacing lactose with microcrystalline cellulose or changing a standard lubricant. Patentability would require a non-obvious technical effect, such as a demonstrated stability improvement, substantially improved content uniformity, or a clinically relevant delivery feature.

What is the Orange Book status of benzphetamine hydrochloride?

The key regulatory reference is the FDA Orange Book listing for the approved benzphetamine hydrochloride reference product and any current abbreviated applications (FDA, 2024a). For an ANDA applicant, the Orange Book review should identify:

• The reference-listed drug
• Approved strengths
• Dosage form
• Therapeutic-equivalence codes
• Listed patents, if any
• Listed exclusivity, if any
• Reference-product discontinuation status
• Any relevant labeling limitations

Because benzphetamine is an old product, commercial entry risk is more likely to arise from market size, manufacturing economics, controlled-substance requirements, and supply-chain compliance than from active listed patents. An applicant should not assume that a low-patent-risk profile eliminates regulatory work. FDA may still require a complete bioequivalence package, drug-master-file support, stability data, and controlled-substance controls.

When does benzphetamine hydrochloride lose exclusivity?

Benzphetamine hydrochloride effectively lost its original market exclusivity decades ago. The product is not comparable to a recently approved obesity medicine with remaining new chemical entity, orphan, pediatric, or new clinical investigation exclusivity.

Exclusivity issue	Commercial assessment
Original compound patent	Expected to be expired
Original product patent	Expected to be expired
NCE exclusivity	Expired
Pediatric exclusivity	No meaningful current commercial relevance identified
Orange Book patent barrier	Expected to be limited for the legacy immediate-release product
Generic entry	Legally feasible subject to FDA approval and market economics

Any final entry decision should rely on the current FDA Orange Book and Drugs@FDA records rather than historical brand information.

Which companies are challenging benzphetamine hydrochloride?

Benzphetamine does not have the type of active Paragraph IV litigation profile associated with high-value branded medicines. The commercial field is primarily a generic supply market rather than a branded-versus-generic litigation market.

Paragraph IV risk

An ANDA applicant may file a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or not infringed. For an old immediate-release product with no meaningful live patent estate, Paragraph IV activity is likely to be limited.

The more important risks are:

• Failure to establish bioequivalence
• Inadequate content uniformity
• Dissolution differences
• Incomplete controlled-substance controls
• Active pharmaceutical ingredient supply interruption
• Low market demand
• Product discontinuation by existing suppliers

What commercial opportunities exist for benzphetamine hydrochloride?

The strongest opportunities are operational rather than clinically innovative.

Generic supply and shortage replacement

A manufacturer can target reliable supply of 25 mg and 50 mg tablets for wholesalers, pharmacies, and institutional buyers. A second-source strategy may be commercially useful if incumbent suppliers have intermittent availability.

Excipient-differentiated products

Potential positioning includes:

• Lactose-free tablets
• Smaller tablets through higher-functionality excipients
• Improved tablet hardness and reduced friability
• Moisture-protective packaging
• Color-coded strengths
• Unit-dose packaging for controlled inventory
• Consistent supply of both tablet strengths

These changes are most valuable when they solve a documented manufacturing, dispensing, or patient-use problem.

505(b)(2) lifecycle product

A 505(b)(2) application could support a modified formulation, but the economic case is challenging. Possible concepts include an orally disintegrating tablet, chewable tablet, or alternative dosing profile. Each would require a clear clinical or commercial rationale and may create additional abuse, pediatric exposure, palatability, and bioavailability concerns.

An extended-release product could offer dosing convenience, but it would enter a market with established stimulant and obesity-treatment alternatives. It would also require more extensive pharmacokinetic and potentially clinical development than a conventional generic tablet.

Contract manufacturing

Controlled-substance manufacturing capability can be a barrier to entry. A company with Schedule III handling, secure storage, reconciliation, diversion monitoring, and DEA-compliant distribution infrastructure could offer contract development and manufacturing services to smaller marketing authorization holders.

How does benzphetamine compare with newer obesity drugs?

Benzphetamine has a lower development and manufacturing burden than a new obesity therapy, but its commercial ceiling is also much lower.

Factor	Benzphetamine hydrochloride	Semaglutide or tirzepatide products
Dosage form	Immediate-release tablet	Injectable or advanced oral formulations
Regulatory age	Legacy product	Modern branded products
Treatment duration	Short-term labeling	Chronic treatment
Controlled substance	Yes	Generally no
Patent complexity	Low relative to newer products	High
Manufacturing complexity	Moderate tablet manufacturing	High, especially for biologics or peptide products
Clinical differentiation	Limited	Weight loss and metabolic outcomes
Price potential	Generic or low-cost	Branded specialty pricing
Main commercial barrier	Small market and controlled-substance compliance	Patent, manufacturing, reimbursement, and supply capacity

Benzphetamine therefore fits a low-cost generic or niche lifecycle strategy, not a premium obesity franchise strategy.

What manufacturing and IP barriers affect benzphetamine hydrochloride?

The principal barriers are:

1. Controlled-substance registration and security requirements.
2. Consistent API supply and analytical control.
3. Low-dose blend uniformity.
4. Moisture and stability management.
5. Bioequivalence and dissolution performance.
6. Commercially viable batch sizes.
7. DEA-compliant forecasting, storage, distribution, and reconciliation.
8. Limited opportunity to recover high formulation-development costs.

Geographic coverage is strongest in the United States, where the reference product, Orange Book framework, and controlled-substance regulations define the pathway. Foreign markets require separate assessments of national approvals, narcotics controls, import permits, and local patent status. A formulation that is commercially viable in the United States may not justify registration in smaller markets because obesity-treatment guidelines and controlled-substance rules differ.

What is the patent strength of benzphetamine hydrochloride?

The patent estate for a conventional benzphetamine hydrochloride immediate-release tablet is weak from a blocking-rights perspective and limited as a platform for new exclusivity. The strongest defensible position would come from a genuinely differentiated formulation supported by comparative data, manufacturing know-how, or a regulated product profile that competitors cannot easily replicate.

Excipient substitution alone is unlikely to create substantial patent value. Trade secrets covering process parameters, supplier qualification, blend control, coating conditions, and packaging configuration may have more practical value than a narrow formulation patent.

Key Takeaways

• Benzphetamine hydrochloride is a legacy Schedule III anorectic supplied primarily as 25 mg and 50 mg immediate-release tablets.
• The original patent and exclusivity barriers are expected to be expired or commercially immaterial.
• The best near-term opportunity is reliable generic supply with strong content-uniformity, dissolution, stability, and controlled-substance controls.
• Lactose-free formulation, moisture-protective packaging, unit-dose presentation, and improved tablet robustness are credible excipient-led differentiators.
• A 505(b)(2) reformulation is possible but carries materially higher development risk than an ANDA.
• Patent value is likely to come from a demonstrated technical effect, not a routine change in filler, binder, or lubricant.
• The principal competitive risks are low market size, newer chronic obesity therapies, controlled-substance compliance, and supply-chain economics.

FAQs

Can benzphetamine hydrochloride be formulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable filler-binder. The replacement must preserve content uniformity, hardness, disintegration, dissolution, and stability.

Is an orally disintegrating benzphetamine tablet commercially attractive?

It could improve administration convenience, but the product would require formulation, palatability, bioequivalence, packaging, and abuse-liability evaluation. The limited market size makes the return on development uncertain.

Does benzphetamine hydrochloride have biosimilar risk?

No. Benzphetamine hydrochloride is a small-molecule drug, not a biologic. The relevant competition is from pharmaceutical-equivalent generic products approved through the ANDA pathway, not biosimilars.

Can a new excipient combination receive patent protection?

Possibly, but routine excipient substitution is unlikely to satisfy the non-obviousness requirement. A patent application would need evidence of an unexpected technical advantage or a difficult-to-reproduce formulation outcome.

What is the most defensible commercial strategy?

The most defensible strategy is a compliant generic or contract-manufacturing product with dependable API sourcing, validated low-dose blending, two-strength availability, barrier packaging, and an excipient profile that removes a practical patient or manufacturing limitation.

References

1. Drug Enforcement Administration. (2024). Controlled substances act: Schedule III controlled substances. U.S. Department of Justice.

2. Food and Drug Administration. (2023a). Benzphetamine hydrochloride tablets prescribing information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

4. National Library of Medicine. (2024). DailyMed: Benzphetamine hydrochloride tablet labeling. U.S. National Library of Medicine.